| Literature DB >> 34250153 |
Simon Görtz1, Suzanne M Tabbaa2, Deryk G Jones3, John D Polousky4, Dennis C Crawford5, William D Bugbee1,2,3,4,5,6, Brian J Cole1,2,3,4,5,6, Jack Farr1,2,3,4,5,6, James E Fleischli1,2,3,4,5,6, Alan Getgood1,2,3,4,5,6, Andreas H Gomoll1,2,3,4,5,6, Allan E Gross1,2,3,4,5,6, Aaron J Krych1,2,3,4,5,6, Christian Lattermann1,2,3,4,5,6, Bert R Mandelbaum1,2,3,4,5,6, Peter R Mandt1,2,3,4,5,6, Raffy Mirzayan1,2,3,4,5,6, Timothy S Mologne1,2,3,4,5,6, Matthew T Provencher1,2,3,4,5,6, Scott A Rodeo1,2,3,4,5,6, Oleg Safir1,2,3,4,5,6, Eric D Strauss1,2,3,4,5,6, Christopher J Wahl1,2,3,4,5,6, Riley J Williams1,2,3,4,5,6, Adam B Yanke1,2,3,4,5,6.
Abstract
BACKGROUND: Osteochondral allograft (OCA) transplantation has evolved into a first-line treatment for large chondral and osteochondral defects, aided by advancements in storage protocols and a growing body of clinical evidence supporting successful clinical outcomes and long-term survivorship. Despite the body of literature supporting OCAs, there still remains controversy and debate in the surgical application of OCA, especially where high-level evidence is lacking.Entities:
Keywords: allografts; articular cartilage; osteochondral allograft; osteochondritis dissecans
Year: 2021 PMID: 34250153 PMCID: PMC8237219 DOI: 10.1177/2325967120983604
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Modified Delphi Process Results to Establish Consensus on Osteochondral Allografts
| Round 1 | Round 2 | Round 3 | |
|---|---|---|---|
| Statements at start of round | 14 | 29 | 25 |
| New or modified statements | 15 | 2 | 13 |
| Statements removed or combined | 0 | 4 | 8 |
| Responses | 23/23 | 21/23 | 18/23 |
Percentage of Agreement and Level of Consensus for Final Statements by Category
| Statement | Agreement, % | Level of Consensus |
|---|---|---|
|
| ||
| OCA indications include symptomatic cartilage defect(s), including defect(s) secondary to trauma, OCD, osteonecrosis, intra-articular fractures in patients of any age, and activity level not suitable for prosthetic replacement. | 100 | Unanimous |
| Relative contraindications for OCA use include uncorrected ligamentous instability, uncorrected malalignment, and end-stage osteoarthritis except in rare instances where used as a bridging procedure. | 100 | Unanimous |
| OCAs can be used to revise previously failed cartilage restoration procedures. | 100 | Unanimous |
| OCAs can be considered a primary treatment for reconstruction of OCD lesions. | 94 | Strong |
| Systematic autoimmune/inflammatory joint disease is not an absolute contraindication to OCA implantation. | 100 | Unanimous |
|
| ||
| Supplemental fixation of an OCA is needed only if the graft is unstable. | 94 | Strong |
| Cysts beneath a lesion being restored with an OCA should be addressed by curettage and bone grafting. | 100 | Unanimous |
| The ideal depth of a femoral OCA recipient site is 6-10 mm. | 100 | Unanimous |
| The osseous component of OCAs should be pulse lavaged with sterile irrigation fluid with or without antibiotics before implantation. | 94 | Strong |
| It is unknown if OCA bone incorporation can be enhanced by biologic adjuncts. | 94 | Strong |
|
| ||
| A contralateral graft is an OCA from the opposite condyle (eg, a lateral condyle for a medial condylar procedure). | 89 | Strong |
| A contralateral OCA can be utilized for single-plug restoration up to 25 mm in diameter. | 100 | Unanimous |
| Femoral condylar OCAs can be adequately size matched using condylar and/or tibial width measured on radiographs with magnification marker or magnetic resonance imaging/computed tomography. | 96 | Strong |
| A standardized method for testing cartilage viability and metabolic activity should be established. | 100 | Unanimous |
|
| ||
| An initial period of partial weightbearing (up to 6 weeks) for tibiofemoral OCA reconstructions is appropriate. | 100 | Unanimous |
| Weightbearing as tolerated in conjunction with extension bracing (up to 6 weeks) after patellar and/or trochlear OCA reconstructions is appropriate. | 100 | Unanimous |
| Time (minimum 12 weeks from surgery) and functional recovery should both be used as criteria to return to impact activities. | 100 | Unanimous |
OCA, osteochondral allograft; OCD, osteochondritis dissecans.
Level of Evidence and Grade of Evidence for Indications for OCA
| Level of Evidence (No. of Studies per Level) | Grade of Evidence | ||||||
|---|---|---|---|---|---|---|---|
| Statement | 1 | 2 | 3 | 4 | 5 | Total | |
| OCA indications include symptomatic cartilage defect(s),
including defect(s) secondary to trauma, OCD,
osteonecrosis, intra-articular fractures in patients of
any age, and activity level not suitable for prosthetic replacement.
| 0 | 1 | 1 | 37 | 0 | 49 | C |
| Relative contraindications for OCA use include
uncorrected ligamentous instability, uncorrected
malalignment, and end-stage osteoarthritis except in
rare instances where used as a bridging procedure.
| 0 | 0 | 0 | 12 | 0 | 12 | C |
| OCAs can be used to revise previously failed cartilage
restoration procedures.
| 0 | 0 | 3 | 8 | 0 | 11 | C |
| OCAs can be considered a primary treatment for
reconstruction of ODC lesions.
| 0 | 0 | 1 | 5 | 0 | 6 | C |
| Systematic autoimmune/inflammatory joint disease is not an absolute contraindication to OCA implantation. | 0 | 0 | 0 | 0 | 0 | 0 | D |
OCA, osteochondral allograft; OCD, osteochondritis dissecans.
References 3, 5, 6, 8, 12 –17, 19, 21 –24, 27, 29, 31 –33, 35, 37, 42, 45, 47 –49, 52, 54, 55, 57, 59, 60, 65, 67, 68, 71, 77, 79, 87.
References 3, 30, 36, 40, 44, 48, 49, 55, 57, 65, 70, 71.
References 2, 17, 26, 32, 34, 39, 46, 56, 66, 76, 86.
Level of Evidence and Grade of Evidence for Surgical Technique
| Level of Evidence (No. of Studies per Level) | Grade of Evidence | ||||||
|---|---|---|---|---|---|---|---|
| Statement | 1 | 2 | 3 | 4 | 5 | Total | |
| Supplemental fixation of an OCA is needed only if the graft is unstable. | 0 | 0 | 0 | 0 | 0 | 0 | D |
| Cysts beneath a lesion being restored with an OCA should be addressed by curettage and bone grafting. | 0 | 0 | 0 | 0 | 0 | 0 | D |
| The ideal depth of a femoral OCA recipient site is 6-10 mm.
| 0 | 0 | 0 | 1 | 1 | 2 | D |
| The osseous component of OCAs should be pulse lavaged
with sterile irrigation fluid with or without
antibiotics before implantation.
| 0 | 0 | 0 | 0 | 5 | 5 | D |
| It is unknown if OCA bone incorporation can be enhanced
by biologic adjuncts.
| 0 | 0 | 1 | 1 | 1 | 3 | C |
OCA, osteochondral allograft.
Level of Evidence and Grade of Evidence for Graft Matching
| Level of Evidence (No. of Studies per Level) | Grade of Evidence | ||||||
|---|---|---|---|---|---|---|---|
| Statement | 1 | 2 | 3 | 4 | 5 | Total | |
| A contralateral graft is an OCA from the opposite
condyle (eg, a lateral condyle for a medial condylar procedure).
| 0 | 0 | 0 | 0 | 2 | 2 | D |
| A contralateral OCA can be utilized for single plug
restoration up to 25 mm in diameter.
| 0 | 0 | 1 | 0 | 4 | 5 | C |
| Femoral condylar OCAs can be adequately size matched
using condylar and/or tibial width measured on
radiographs with magnification marker or MRI/CT.
| 0 | 0 | 1 | 0 | 1 | 2 | C |
| A standardized method for testing cartilage viability and metabolic activity should be established. | 0 | 0 | 0 | 0 | 0 | 0 | D |
CT, computed tomography; MRI, magnetic resonance imaging; OCA, osteochondral allograft.
Level of Evidence and Grade of Evidence for Rehabilitation and Return to Sports
| Level of Evidence (No. of Studies per Level) | Grade of evidence | ||||||
|---|---|---|---|---|---|---|---|
| Statement | 1 | 2 | 3 | 4 | 5 | Total | |
| An initial period of partial weightbearing (up to 6
weeks) for tibiofemoral OCA reconstructions is appropriate.
| 0 | 0 | 0 | 12 | 0 | 12 | C |
| Weightbearing as tolerated in conjunction with extension
bracing (up to 6 weeks) after patellar and/or trochlear
OCA reconstructions is appropriate.
| 0 | 0 | 0 | 2 | 0 | 2 | C |
| Time (minimum 12 weeks from surgery) and functional recovery should both be used as criteria to return to impact activities. | 0 | 0 | 0 | 0 | 0 | 0 | D |
OCA, osteochondral allograft.
References 2, 17, 19, 26, 31, 43, 45, 53, 54, 59, 60, 69.
Inclusion/Exclusion Criteria
| Inclusion Criteria | Exclusion Criteria |
|---|---|
| Clinical studies (evidence levels 1-4) reporting outcomes of osteochondral allograft transplantation of the knee | Book chapters, conference proceedings, presentations |
| Basic science studies | Expert opinion articles |
| Systematic reviews | Review papers |
| Fresh osteochondral allografts | <5 patients |
| Decellularized allografts, frozen allografts, or synthetic osteochondral grafts, bipolar |
Levels of Evidence From the Centre of Evidence-Based Medicine
| Level | Type of Evidence |
|---|---|
| 1A | Systematic review (with homogeneity) of RCTs |
| 1B | Individual RCT (with narrow CIs) |
| 1C | All-or-none study |
| 2A | Systematic review (with homogeneity) of cohort studies |
| 2B | Individual cohort study (including low-quality RCT) |
| 2C | “Outcomes” research, ecological studies |
| 3A | Systematic review (with homogeneity) of case-control studies |
| 3B | Individual case-control study |
| 4 | Case series (and poor-quality cohort and case-control study) |
| 5 | Expert opinion without explicit critical appraisal or based on physiology bench research or “first principles” |
RCT, randomized controlled trial.